Graft failure occurs when a transplanted organ or tissue stops functioning adequately, and it remains one of the most serious complications in transplant medicine. The causes range from the immune system mounting an attack on the foreign tissue to damage sustained during the surgical process itself, and even to everyday factors like whether a patient takes medications on schedule. Recognizing the warning signs early and understanding the expanding toolkit of treatments can make a meaningful difference in whether a graft survives for years or decades.
How the Immune System Attacks a Transplant
The most common driver of graft failure is the recipient’s immune system recognizing the transplanted organ as foreign and trying to destroy it. This immune response falls into two broad categories, and they work through different mechanisms.
The first is cellular rejection, driven primarily by T cells. These immune cells detect proteins on the surface of the donor organ that differ from the recipient’s own. Once activated, they infiltrate the graft tissue and cause direct damage. Repeated episodes of this T cell-driven rejection have been linked to the gradual development of chronic dysfunction and eventual graft loss.1PubMed Central. An Immune Atlas of T Cells in Transplant Rejection: Pathways and Therapeutic Opportunities The process involves recognition of foreign tissue, activation of both helper and killer T cell populations, and their migration into the graft where they inflict damage.2PubMed Central. Mechanism of cellular rejection in transplantation
The second is antibody-mediated rejection, where the recipient produces antibodies that target the donor organ’s blood vessel lining. These donor-specific antibodies cause injury through several pathways, including activating the complement system (a cascade of proteins that punches holes in cells) and directly stimulating the vessel walls to thicken. Antibodies that strongly bind complement proteins, particularly those of the IgG3 subtype, tend to cause more severe, acute injury and early graft failure. By contrast, antibodies that do not bind complement as effectively are more often associated with a slower, smoldering form of chronic rejection.3PubMed Central. Donor-Specific Antibodies in Kidney Transplant Recipients
Over time, either form of rejection can lead to chronic allograft dysfunction, which is characterized by progressive narrowing of the graft’s blood vessels and scarring of its tissue. This slow strangling of the organ’s blood supply ultimately produces ischemia, cell death, and irreversible failure.4Oxford Academic (Burns & Trauma). Chronic allograft rejection: A significant hurdle to transplant success
Damage That Has Nothing to Do With Rejection
Not all graft failure stems from the immune system. A significant share of early transplant complications traces back to the physical ordeal the organ endures during procurement, transport, and implantation.
Ischemia-reperfusion injury is the most important of these non-immune causes. When an organ is removed from the donor, its blood supply is cut off (ischemia). Once it is connected to the recipient’s circulation, blood rushes back in (reperfusion). That sudden return of oxygen triggers a wave of inflammation, oxidative stress, and cell death pathways that can severely damage the graft before the immune system even enters the picture.5PubMed Central. Ischaemia-Reperfusion Injury in Organ Transplantation: Role of Coenzyme Q10 In kidney transplants, prolonged cold storage time is strongly linked to delayed graft function, where the new kidney does not produce urine immediately after surgery. Research has shown that longer cold ischemia times lead to greater infiltration of inflammatory cells into the kidney’s filtering units, which worsens early outcomes.6PubMed Central. Ischemia/reperfusion injury in human kidney transplantation: an immunohistochemical analysis of changes after reperfusion
The very drugs used to prevent rejection can also contribute to graft damage. Calcineurin inhibitors, the backbone of most immunosuppression regimens, are toxic to the kidney at high levels over long periods. That said, the picture is nuanced: one analysis found that calcineurin inhibitor toxicity was the primary cause of graft loss in fewer than 1% of cases, though it was considered a contributing factor in roughly one in five cases of graft loss.7PubMed Central. Calcineurin Inhibitor Associated Nephrotoxicity in Kidney Transplantation—A Transplant Nephrologist’s Perspective So while drug toxicity matters, it is rarely the sole culprit.
Recognizing the Warning Signs
Graft failure does not usually announce itself with a single dramatic event. More often, it is a gradual process that shows up first in lab values and subtle clinical changes before the patient feels anything is obviously wrong.
In kidney transplants, the most common red flags are a rising creatinine level (indicating the kidney is filtering less effectively), increasing protein in the urine, and a declining glomerular filtration rate. Research into late kidney transplant biopsies has confirmed that grafts destined for failure show higher rates of proteinuria and faster deterioration in function in the months leading up to the biopsy, compared to stable grafts.8JCI Insight. A molecular classifier for predicting future graft loss in late kidney transplant biopsies In heart transplants, the parallel problem is cardiac allograft vasculopathy, a diffuse thickening of the coronary arteries that can silently reduce blood flow to the heart muscle. Because transplant recipients often lack typical chest pain (the transplanted heart’s nerves are cut), this vasculopathy is frequently detected only through routine screening with coronary angiography or intravascular ultrasound.9PubMed Central. Cardiac allograft vasculopathy: a review
For decades, tissue biopsy has been the gold standard for diagnosing rejection, but it is invasive and carries its own risks. A newer approach uses a simple blood test to measure donor-derived cell-free DNA, which are tiny fragments of the donor organ’s DNA that leak into the recipient’s bloodstream when graft cells are injured or dying. A large study involving over 2,800 kidney transplant recipients found that these DNA levels correlated strongly with all forms of rejection and improved the accuracy of predicting rejection beyond standard monitoring alone.10Nature Medicine. Cell-free DNA for the detection of kidney allograft rejection Earlier work established a practical threshold: levels below 1% generally indicate the absence of active rejection, while levels above 1% suggest a meaningful probability of rejection, with particularly strong ability to detect antibody-mediated rejection.11PubMed Central. Cell-Free DNA and Active Rejection in Kidney Allografts This kind of blood-based monitoring could eventually reduce the need for routine biopsies, though it has not fully replaced them yet.
Treating Rejection When It Happens
When acute rejection is caught, the first line of defense is almost always high-dose corticosteroids. This approach has been used since the earliest days of transplantation and remains effective, reversing rejection in roughly 60% of episodes in classic studies.12PubMed. Treatment of acute allograft rejection with high doses of corticosteroids When steroids fail, the next step typically involves powerful antibody therapies that deplete the T cells responsible for the attack. Anti-thymocyte globulin (ATG) has long been the standard for steroid-resistant rejection. An alternative, alemtuzumab, showed comparable rejection reversal rates to ATG in one trial, with a treatment failure rate of about 27% versus 40% for ATG, though the difference was not statistically significant. Alemtuzumab did cause far fewer infusion-related side effects and cost roughly half as much.13American Journal of Transplantation. Treatment of Steroid-Resistant Acute Renal Allograft Rejection With Alemtuzumab
Antibody-mediated rejection is harder to treat because the problem is not just immune cells but circulating antibodies. The standard approach combines high-dose steroids, plasmapheresis (which physically filters antibodies out of the blood), and high-dose intravenous immunoglobulin. In cases with a mixed cellular component, anti-thymocyte globulin is added. More recently, rituximab, a drug that targets B cells (the antibody factories), has been increasingly incorporated into treatment, particularly for early antibody-mediated rejection in high-risk patients.14PubMed Central. Rituximab in antibody-mediated rejection following kidney transplantation: clinical and pathological outcomes
The treatment landscape for antibody-mediated rejection is evolving rapidly. Recent phase 2 trial results with CD38 antibodies, which target the plasma cells that produce harmful antibodies, have shown promise in reversing active rejection. Several other approaches are in clinical trials, including complement inhibitors that block the downstream damage caused by antibodies, drugs that intercept the antibodies before they can bind, and anti-inflammatory agents that target the cellular inflammation triggered by antibody attachment to blood vessel walls.15PubMed Central. Antibody-mediated rejection-treatment standard None of these newer agents has a full regulatory approval for this specific use yet, but the pipeline represents the most active period of drug development in transplant rejection in years.
When Graft Failure Leads to Retransplantation
When all treatment efforts fail and a graft is lost, the question of retransplantation arises. This is a viable option for many patients, though outcomes tend to be somewhat worse than for a first transplant. A study of kidney retransplantation identified several independent risk factors for poorer graft survival: being 50 or older, spending more than a year on dialysis between transplants, having the first graft survive less than two years, having other significant medical conditions, active smoking, and having experienced life-threatening surgical complications during the first transplant.16PubMed Central. Kidney Retransplantation after Graft Failure: Variables Influencing Long-Term Survival The takeaway for patients is that managing the interval on dialysis and addressing modifiable risk factors like smoking can improve the odds of a successful second transplant.
Graft Failure in Bone Marrow and Stem Cell Transplants
Graft failure is not limited to solid organ transplants. In hematopoietic stem cell transplantation (bone marrow transplants), primary graft failure means the donated stem cells never engraft and start producing blood cells. This is a different beast from organ rejection: instead of a functioning organ being slowly destroyed, the transplanted cells simply fail to take hold in the bone marrow.
Risk factors differ accordingly. In patients receiving non-myeloablative transplants with a particular post-transplant drug regimen, primary graft failure was significantly more likely in those aged 65 or older, those with certain blood cancers, and those who developed a specific viral reactivation after transplant. Receiving a higher dose of stem cells in the graft was protective.17Transplantation and Cellular Therapy. Graft Failure Incidence, Risk Factors, and Outcomes in Patients Undergoing Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide Unlike organ transplant rejection, which can sometimes be reversed pharmacologically, primary graft failure in stem cell transplants often requires a second transplant or a backup infusion of the patient’s own stored cells, making prevention through optimized cell doses and donor selection critical.
Why Some Organs Fail More Often Than Others
The transplanted organ’s biology shapes its vulnerability to failure. In heart transplants, the dominant long-term threat is cardiac allograft vasculopathy, which produces a diffuse, concentric thickening of the coronary arteries rather than the focal blockages typical of ordinary coronary artery disease. Both immune and non-immune factors, including high cholesterol, viral infections, and the chronic effects of immunosuppression, contribute to the endothelial injury that drives this process.9PubMed Central. Cardiac allograft vasculopathy: a review
Corneal transplants occupy the opposite end of the spectrum. The eye is one of the body’s immune-privileged sites, meaning the immune system is naturally restrained from mounting full-blown attacks there. As a result, corneal grafts enjoy long-term survival rates between 50% and over 90%, depending on the degree of tissue mismatch. By comparison, skin grafts placed across the same genetic barriers fail in virtually 100% of cases.18PubMed Central. Corneal transplantation and immune privilege This dramatic difference underscores how much the local tissue environment matters alongside the standard matching and immunosuppression calculus.
The Adherence Problem
One of the most frustrating contributors to graft failure is something entirely within the patient’s control: taking medications and showing up for appointments. Immunosuppressive drugs must be taken consistently, often for life, and skipping doses gives the immune system a window to mount an attack.
The numbers are sobering. In one study of kidney transplant recipients, non-adherent patients had more than six times the odds of graft loss compared to adherent patients, along with roughly double the odds of rejection and nearly triple the odds of death.19PubMed Central. Is Non-Adherence Associated with Adverse Outcomes in Kidney Transplant Recipients? The Role of Non-Adherence as a Risk and Predictor Factor for Graft Loss and Death Missed clinic appointments compound the problem: patients who missed 12% or more of their scheduled visits had about 50% higher rates of acute rejection and a 65% higher risk of graft loss even after accounting for other factors. The combination of missing appointments and skipping medications was especially dangerous, more than quadrupling the risk of graft loss compared to patients who were adherent on both counts.20PubMed Central. The Impact of Health Care Appointment Non-Adherence on Graft Outcomes in Kidney Transplantation Non-adherence is a particularly large concern in younger transplant recipients, who face decades of medication regimens and may struggle more with the daily discipline involved.21PubMed. Non-adherence to immunosuppressive medications in kidney transplant recipients- a systematic scoping review
Socioeconomic Factors That Shape Outcomes
Where you live and how much economic support you have also influence whether a graft survives. Research using area-level deprivation indices has consistently found that transplant recipients living in the most disadvantaged neighborhoods face worse outcomes. In liver transplantation, five-year graft survival was about two percentage points lower for recipients in high-deprivation areas, and the risk accelerated above the median level of deprivation rather than increasing in a steady, linear fashion.22Liver Transplantation. Socioeconomic deprivation is associated with worse patient and graft survival following adult liver transplantation In kidney transplantation, employment status and insurance coverage consistently influenced graft failure over time, while education level became a significant factor only in later years after transplant.23PubMed Central. Longitudinal Changes in the Impact of Socioeconomic Status on Graft Failure in Kidney Transplantation
After a graft fails, socioeconomic disparities continue to matter. An analysis of Australian and New Zealand patients whose first kidney transplant failed found that those from the most disadvantaged areas were 30% less likely to receive a second transplant and 37% more likely to die on dialysis, compared to patients from the least disadvantaged areas.24PubMed. Socio-economic disparity, access to care and patient-relevant outcomes after kidney allograft failure These disparities likely reflect a tangle of factors: transportation barriers, difficulty affording co-pays or time off work, less access to transplant centers, and potentially implicit biases in referral patterns.
The Emotional Toll of Graft Loss
The psychological dimension of graft failure is often underappreciated. Losing a transplant means returning to dialysis or a waiting list, and the emotional weight of that reversal is substantial. A systematic review of patient experiences identified three interconnected phases that people move through: a shattering of the lifestyle and plans they had built around a functioning transplant, a period of physical and psychological turbulence, and eventually a re-alignment as they develop strategies to move forward.25PubMed. Perspectives and experiences of kidney transplant recipients with graft failure: A systematic review and meta-synthesis Transplant teams increasingly recognize that psychosocial support needs to be an integral part of post-failure care, not an afterthought.
Prevention Before Transplant and Emerging Technologies
Prevention starts before surgery. Tissue matching and crossmatching, where a donor and recipient’s immune compatibility is assessed, remain the foundation of transplant success. Crossmatching has evolved from purely laboratory-based tests to virtual crossmatching, where detailed antibody profiles stored in databases allow clinicians to predict compatibility without a physical test for every potential donor-recipient pair. This approach has made organ allocation faster and more efficient.26PubMed Central. Out with the old, in with the new: Virtual versus physical crossmatching in the modern era
One of the more exciting recent advances targets the ischemia-reperfusion injury problem directly. Normothermic machine perfusion keeps a donated organ warm and supplied with oxygenated blood during transport, rather than simply packing it on ice. In liver transplants from donors whose hearts had stopped (a category historically associated with higher failure rates), machine perfusion was associated with substantially better two-year graft survival compared to standard cold storage: about 91% versus roughly 82% after matching for other factors. Recipients in the machine perfusion group also had a dramatically lower risk of graft failure overall.27PubMed Central. Normothermic Machine Perfusion Is Associated With Improvement in Mortality and Graft Failure in Donation After Cardiac Death Liver Transplant Recipients in the United States This technology is spreading to kidney and heart transplantation as well, and it has the potential to expand the pool of usable donor organs by rehabilitating marginal grafts that would previously have been discarded.
Further ahead, gene-editing technologies like CRISPR are being applied to xenotransplantation research, where the goal is to modify pig organs so that they can be transplanted into humans without triggering immediate rejection. The modifications target genes responsible for producing the surface molecules that the human immune system recognizes as foreign, as well as inserting human-compatible genes to regulate complement activation and blood clotting.28PubMed Central. CRISPR/Cas Technology in Pig-to-Human Xenotransplantation Research Several high-profile cases of pig-to-human heart and kidney transplants have already been performed, though long-term survival remains a challenge. If the engineering obstacles can be overcome, xenotransplantation could eventually address the organ shortage that forces patients onto years-long waiting lists and makes retransplantation after graft failure so difficult to access.